Transgenomic, Inc. (TBIO) Licenses Exclusive Rights To Multiplexed ICE COLD-PCRTM Technology
5/28/2014 8:53:28 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).
Help employers find you! Check out all the jobs and post your resume.
comments powered by